Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Icon ( (ICLR) ) has shared an update.
On September 4, 2025, ICON plc confirmed that there would be no changes to its financial guidance for the full year 2025, following the announcement of a CEO transition. This confirmation reassures stakeholders about the company’s stability and continuity in its financial outlook despite the leadership change.
The most recent analyst rating on (ICLR) stock is a Buy with a $236.00 price target. To see the full list of analyst forecasts on Icon stock, see the ICLR Stock Forecast page.
Spark’s Take on ICLR Stock
According to Spark, TipRanks’ AI Analyst, ICLR is a Outperform.
Icon’s overall stock score reflects its strong financial health and positive technical indicators, despite some challenges in revenue growth and elevated cancellations. The company’s strategic focus on growth areas and efficient operations support a favorable outlook.
To see Spark’s full report on ICLR stock, click here.
More about Icon
ICON plc operates in the healthcare industry, providing outsourced development services to the pharmaceutical, biotechnology, and medical device sectors. The company focuses on clinical development services and is headquartered in Dublin, Ireland.
Average Trading Volume: 1,282,779
Technical Sentiment Signal: Sell
Current Market Cap: $13.83B
Find detailed analytics on ICLR stock on TipRanks’ Stock Analysis page.